Off-label Firazyr Use Found Safe in Small Study, but Biomarkers May Help

Off-label Firazyr Use Found Safe in Small Study, but Biomarkers May Help

293989

Off-label Firazyr Use Found Safe in Small Study, but Biomarkers May Help

Firazyr (icatibant), when used off-label to treat acute non-hereditary angioedema, can elicit different treatment responses, and its use — and best use — needs to be better understood by doctors treating attacks in this patient group, a real-world study from Australia reports. Biomarkers that could more easily distinguish histamine-mediated angioedema from attacks triggered by the overproduction of bradykinin, a pro-inflammatory peptide, are also needed, its researchers wrote. Bradykinin is the cause of all forms of hereditary angioedema…

You must be logged in to read/download the full post.